Pnd6 Value of Budget Impact Analysis Based on Epidemiologic Data: Insights From Multiple Sclerosis in Sao Paulo, Brazil

Silva, AL Ferreira Da; Filkelsztejn, A; Ribeiro, Rosina Trevisan Martins; Polanczyk, CA

doi:10.1016/s1098-3015(11)72587-6

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Information for the review was provided from three countries (Brazil, Argentina and Colombia). Main characteristics of included studies are shown in Tables 1 and 2. Only two studies were published as full texts 33,34 and the other five studies were presented as abstracts in regional meetings [30][31][32]35,36 . The studies were heterogeneous in many aspects including objectives, outcomes and sources of information.…”

Section: Resultsmentioning

confidence: 99%

“…The three studies that addressed DMT use, direct costs and some adherence of MS patients were performed in Brazil 32,35,36 . Two studies determined the distribution of MS-specific treatments in the Brazilian Public Healthcare System and the public pharmaceutical expenditures in MS patients in Brazil during [2006][2007][2008][2009].…”

mentioning

confidence: 99%

“…In another study, Ferreira da Silva et al 36 performed a cross-sectional study in Sao Paulo, Brazil that focused on coverage of DMT treatment in MS patients. It was reported that the number of patients on DMT treatment in 2009 in the Sao Paulo region was 1319 patients, resulting in a prevalence of 11.9 cases per 100,000 inhabitants of RRMS patients.…”

mentioning

confidence: 99%

See 2 more Smart Citations

There is much to be learnt about the costs of multiple sclerosis in Latin America

Romano

Machnicki

Rojas

et al. 2013

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

ARTICLE VIEW AND REVIEW There is much to be learnt about the costs of multiple sclerosis in Latin AmericaHay mucho a ser aprendido sobre los costos de la esclerosis múltiple en América Latina ABSTRACTWe assessed the health economic data of multiple sclerosis (MS) in Latin America (LA). Method: A systematic review of the literature from 1990 to 2011 was conducted. Outcome measures included: mean cost of disease modifying therapies (DMTs), mean cost of treatment of relapses and mean cost of disease by stage stratification measured by the expanded disability status scale (EDSS). Results: Seven studies from three countries (Brazil, Argentina and Colombia) were included. In 2004, in Argentina, the mean cost of DMT treatment was reported to be USD 35,000 per patient treated. In Brazil, the total MS expenditure of DMTs rose from USD 14,011,700 in 2006 to USD 122,575,000 in 2009. Patient costs ranged between USD 10,543 (EDSS 8-9.5) and USD 25,713 (EDSS 3-5.5). Indirect costs markedly increased for the EDSS 8-9.5 patients. Conclusion: Further research assessing the economic burden of MS in LA is warranted.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

There is much to be learnt about the costs of multiple sclerosis in Latin America

Romano

Machnicki

Rojas

et al. 2013

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…In a systematic review of health economic data of MS in LATAM 3 – 8 from January 1990 to September 2011, the estimated yearly costs of treatment in RRMS in Argentina 2004 was in US dollars (USD): 5 GA $35,280, IFN beta-1a 44 mcg $43,080 and IFN beta-1a 30 mcg, $29,256. The source of pharmacy data was taken from the market and it possibly overestimated the cost of DMTs.…”

Section: Introductionmentioning

confidence: 99%

Disease-modifying therapies in multiple sclerosis in Latin America

Skromne-Eisenberg¹,

Ordoñez-Boschetti

Treviño‐Frenk

2017

Multiple Sclerosis Journal - Experimental, Translational and Cl

View full text Add to dashboard Cite

The treatment of multiple sclerosis (MS) has become increasingly complex during the last 10 years, mainly because of the advent of new and more potent disease-modifying therapies (DMTs). In Latin America, the therapeutic repertoire available for MS treatment is similar to the one in the rest of the world, but the high costs of these drugs, in conjunction with the limited resources of the social security health systems, makes the treatment of MS more difficult. For neurologists in Latin America, providing personalized MS treatment has become a challenge. We present a review of the status of the DMT in Central and South America, benefits as well as limitations for providing full access to these medications in Latin America.

show abstract

Pnd6 Value of Budget Impact Analysis Based on Epidemiologic Data: Insights From Multiple Sclerosis in Sao Paulo, Brazil

Cited by 2 publications

References 0 publications

There is much to be learnt about the costs of multiple sclerosis in Latin America

There is much to be learnt about the costs of multiple sclerosis in Latin America

Disease-modifying therapies in multiple sclerosis in Latin America

Contact Info

Product

Resources

About